News | November 07, 2024
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
US Generics grew 5% to Rs. 467 Crores for the quarter
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated
